Lakefront Biotherapeutics American Depositary Shares
LKFT
76 hedge funds and large institutions have $960M invested in Lakefront Biotherapeutics American Depositary Shares in 2026 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 28 reducing their positions, and 21 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
1.29% more ownership
Funds ownership: 47.44% → 48.73% (+1.3%)
2% more capital invested
Capital invested by funds: $938M → $960M (+$22.5M)
7% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 28
16% less funds holding
Funds holding: 90 → 76 (-14)
62% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 21
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $15.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAP
Madison Avenue Partners
New York
|
+$27.9M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$14M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.93M |
| 4 |
Renaissance Technologies
New York
|
+$2.62M |
| 5 |
Millennium Management
New York
|
+$2.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
-$12.8M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$4.33M |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$2.87M |
| 4 |
Man Group
London,
United Kingdom
|
-$2.41M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.33M |
LKFT Hedge Fund Activity: Q2 2026 in Review
76 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q2 2026, worth a combined $960M — up 2.4% from $938M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of LKFT and 8 opened new positions — a net loss of 13 holders — while 28 trimmed existing stakes and 26 added.
The largest buyer was Madison Avenue Partners, adding an estimated $27.9M. The largest seller was Segall Bryant & Hamill, exiting entirely with an estimated $12.8M sold.
- 76 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q2 2026, down from 90 in Q1 2026.
- Funds reported $960M of Lakefront Biotherapeutics American Depositary Shares stock for Q2 2026, up 2.4% quarter-over-quarter.
- 8 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q2 2026 and 21 closed out, a net change of -13 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q2 2026 was Madison Avenue Partners, an estimated $27.9M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q2 2026 was Segall Bryant & Hamill, an estimated $12.8M sold.
Based on aggregated 13F filings for Q2 2026.